AG
CRSP icon

AmeriFlex Group’s CRISPR Therapeutics CRSP Stock Holding History

AmeriFlex Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.7K Hold
225
– – 0.01% 717
2025
Q4 		$11.8K Buy
225
+115
+105% +$6.89K 0.01% 696
2025
Q3 		$7.13K Sell
110
-145
-57% -$8.32K ﹤0.01% 851
2025
Q2 		$11.9K Sell
255
-600
-70% -$23.2K 0.01% 672
2025
Q1 		$29.1K Hold
855
– – 0.01% 607
2024
Q4 		$35.6K Buy
+855
New +$40.4K 0.02% 512

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AmeriFlex Group's CRSP Position: Q1 2026 in Review

AmeriFlex Group held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 225 shares worth $10.7K. The position accounts for 0.01% of the portfolio, ranked #717.

AmeriFlex Group first reported a position in CRSP in Q4 2024 and has held it in 6 quarters since. The position peaked at $35.6K in Q4 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • AmeriFlex Group held 225 shares of CRISPR Therapeutics worth $10.7K as of Q1 2026.
  • AmeriFlex Group left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up 0.01% of AmeriFlex Group's portfolio in Q1 2026, its #717 holding.
  • AmeriFlex Group first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • AmeriFlex Group's CRISPR Therapeutics position peaked at $35.6K in Q4 2024.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on AmeriFlex Group's 13F filing for Q1 2026, filed 15 May 2026.